Journal article
Sentinel Modular Program for Propensity Score-Matched Cohort Analyses: Application to Glyburide, Glipizide, and Serious Hypoglycemia
Epidemiology (Cambridge, Mass.), Vol.28(6), pp.838-846
11/2017
DOI: 10.1097/EDE.0000000000000709
PMCID: PMC6554646
PMID: 28682851
Abstract
Sentinel is a program sponsored by the US Food and Drug Administration to monitor the safety of medical products. We conducted a cohort assessment to evaluate the ability of the Sentinel Propensity Score Matching Tool to reproduce in an expedited fashion the known association between glyburide (vs. glipizide) and serious hypoglycemia. Thirteen data partners who contribute to the Sentinel Distributed Database participated in this analysis. A pretested and customizable analytic program was run at each individual site. De-identified summary results from each data partner were returned and aggregated at the Sentinel Operations Center. We identified a total of 198,550 and 379,507 new users of glyburide and glipizide, respectively. The incidence of emergency department visits and hospital admissions for serious hypoglycemia was 19 per 1000 person-years (95% confidence interval = 17.9, 19.7) for glyburide users and 22 (21.6, 22.7) for glipizide users. In cohorts matched by propensity score based on predefined variables, the hazard ratio (HR) for glyburide was 1.36 (1.24, 1.49) versus glipizide. In cohorts matched on a high-dimensional propensity score based on empirically selected variables, for which the program ran to completion in five data partners, the HR was 1.49 (1.31, 1.70). In cohorts matched on propensity scores based on both predefined and empirically selected variables via the high-dimensional propensity score algorithm (the same five data partners), the HR was 1.51 (1.32, 1.71). These findings are consistent with the literature, and demonstrate the ability of the Sentinel Propensity Score Matching Tool to reproduce this known association in an expedited fashion.See video abstract at, http://links.lww.com/EDE/B275.
Details
- Title: Subtitle
- Sentinel Modular Program for Propensity Score-Matched Cohort Analyses: Application to Glyburide, Glipizide, and Serious Hypoglycemia
- Creators
- Meijia Zhou - From the aCenter for Pharmacoepidemiology Research and Training, Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; bDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; cDepartment of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA; dCenter for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD; and eDepartment of Epidemiology, College of Public Health, University of Iowa, Iowa City, IAShirley V WangCharles E LeonardJoshua J GagneCandace FullerChristian HamppPatrick ArchdeaconSengwee TohAarthi IyerTiffany Siu WoodworthElizabeth CavagnaroCatherine A PanozzoSophia AxtmanRyan M CarnahanElizabeth A ChrischillesSean Hennessy
- Resource Type
- Journal article
- Publication Details
- Epidemiology (Cambridge, Mass.), Vol.28(6), pp.838-846
- DOI
- 10.1097/EDE.0000000000000709
- PMID
- 28682851
- PMCID
- PMC6554646
- NLM abbreviation
- Epidemiology
- ISSN
- 1531-5487
- eISSN
- 1531-5487
- Publisher
- United States
- Grant note
- R01 AG025152 / NIA NIH HHS R00 HS022193 / AHRQ HHS HHSF223200910006I / FDA HHS R01 DK102694 / NIDDK NIH HHS
- Language
- English
- Date published
- 11/2017
- Academic Unit
- Pharmacy; Epidemiology; Injury Prevention Research Center
- Record Identifier
- 9983995012402771
Metrics
35 Record Views